Clinical Trials & Research

clinical trialsMany of today's most effective standard treatments are based on the results of previous clinical studies, and many cancer patients are now living longer because of progress made through clinical trials. Clinical trials offer high quality cancer care and also allow patients the opportunity to advance scientific knowledge and help future patients. Ongoing research is essential in the fight against cancer, and it is one of the major objectives of the Edwards Comprehensive Cancer Center.

The Charles H. McKown, Jr., MD, Translational Genomic Research Institute (TGRI), which is housed on the third floor of the Edwards Comprehensive Cancer Center, offers the appropriate environment for performing leading-edge cancer research and conducting clinical trials that are helping to shape the future of cancer research — and not just in Huntington.

ChemoID®, the first chemosensitivity assay against both cancer stem cells and bulk of tumor cells for patients, was developed by researchers, physicians and scientists working in the Translational Genomic Research Institute (TGRI) and it is now in use in the United States as well as other countries around the world.

“The goal of cancer research at the TGRI is to directly affect the disease outcome by taking innovative technologies and novel drugs from the bench to the bedside,” said Dr. Pier Paolo Claudio, who was instrumental in developing ChemoID®. “This approach saves lives and reduces healthcare costs. The research we conduct at the TGRI in collaboration with the Edwards Comprehensive Cancer Center will have a far-reaching impact on people suffering with cancer around the world.”

Clinical trials currently available

Code Description
ABI-007-MBC-001 A Phase II/III, Multi-Center, Open-Label, Randomized Study of Weekly Nab®- Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared To Gemcitabine/Carboplatin, As First Line Treatment In Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer
B-49 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer.
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer.
N093B Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer.
NSABP B-43 A Phase III Clinical Trial Comparing Trastuzumab (Herceptin) Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.
NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cycloshospamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk node negative HER2-Low Invasive Breast Cancer.
RTOG 1005 A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer.
RU011201I A randomized Phase III Trial of Eribulin compared to standard weekly paclitaxel as first- or second-line therapy for locally recurrent or metastatic breast cancer (Eisai protocol # E7389-A001-303)
S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
  • Page last updated: Jul 3, 2014
  • Share to Facebook Share to Twitter More...
Search in:

Show search options